% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

  • greenshotshut greenshotshut Jun 14, 2013 3:15 PM Flag

    Infinity Pharmaceuticals shares 'too cheap to ignore,' says Piper Jaffray. $50 target.

    Piper Jaffray recommends buying Infinity Pharmaceuticals shares after the company's ASCO oral presentation of IPI-145 Phase I data in lymphoma patients. Piper says shares are "too cheap to ignore" and keeps an Overweight rating on the name with a $50 price target.

    Sentiment: Strong Buy

8.68+0.36(+4.33%)Nov 25 4:00 PMEST